On August 13, 2015 Hemispherx Biopharma (NYSE MKT: HEB) reported its financial results for the six months ended June 30, 2015 (Press release, Hemispherx Biopharma, AUG 13, 2015, http://www.hemispherx.net/content/investor/default.asp?goto=836 [SID:1234507244]). The net loss (including non-cash effects) was approximately $8,290,000 or $(0.04) per share as compared to a net loss of $8,792,000 or ($0.05) per share for the same six month period in 2014.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cash, cash equivalents and marketable securities were approximately $15,714,000 at June 30, 2015 as compared to $16,108,000 as of December 31, 2014.
We have recently expanded our international collaborative programs with both major components of our treatment platform (Ampligen, an experimental therapeutic, and Alferon N, and FDA approved commercial product, more fully described below) to create an expanded patient access path while seeking formal approval in the European Union, Australia, and New Zealand.
Also, we have recently initiated new programs in potential cancer therapy, based on a novel concept of synergy in cancer immunotherapy. The medical concept of therapeutic synergy is to use the highly selective Toll-like Receptors (TLR3) agonist, such as Ampligen, in combination with other immune therapeutic treatment to modify the immune microenvironment and potentially increase the number of patients anticipated to respond to such treatment. This concept is supported by preclinical studies in tumor models demonstrating certain interactions as well as results from early clinical studies.
Our overall objectives also include plans to continue seeking approval for commercialization of Ampligen in the United States and abroad as well as to widen existing commercial therapeutic indications of Alferon N Injection presently approved for sales in the United States and Argentina. In addition, we have formed collaborations with multiple research laboratories around the world to examine Ampligen, an experimental therapeutic, and Alferon N, an FDA-approved commercial product (for refractory venereal warts (HPV)) as potential preventatives for, and treatments of, Ebola Virus Disease (EVD) and other hazardous viruses including pandemic influenza and Middle East Respiratory Syndrome (MERS). Our ability to commercialize our products, widen commercial therapeutic indications of Alferon N Injection and/or capitalize on our collaborations with research laboratories to examine our products as potential preventatives for, and treatments of newly emerging viral diseases are subject to a number of significant risks and uncertainties including, but not limited to, our ability to enter into more definitive agreements with some of the research laboratories and others that we are collaborating with, to fund and conduct additional testing and studies, whether or not such testing is successful or requires additional testing and meets the requirements of the FDA and comparable foreign regulatory agencies. We do not know when, if ever, our products will be generally available for commercial sale for any new indications.